Literature DB >> 21739222

F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study.

Amburanjan Santra1, Rakesh Kumar, Punit Sharma, Chandrashekhar Bal, Pramod Kumar Julka, Arun Malhotra.   

Abstract

INTRODUCTION: Recurrent gliomas are usually histologically high grade; either due to recurrence of a de novo high-grade primary or anaplastic transformation in case of low-grade tumors. Survival in these patients is variable. The objective of the present study is to evaluate the role of FDG PET-CT for predicting survival in a large group of patients with suspected recurrent glioma.
METHODS: A total of 81 previously treated histopathologically proven glioma patients; with clinical and conventional imaging findings suspicious of recurrence were included in this study. All patients underwent FDG PET-CT study. Based on tumor to white matter (T/W) and tumor to grey matter (T/G) ratios, all lesions were scored on PET-CT (PET scores 0, 1 and 2). Patients were followed up clinically and by repeated imaging. Data was censored, if the patient died of disease or at the end of the study. Survival analysis was done for each variable employing univariate analysis followed by multivariate analysis, using variables found significant on univariate analysis.
RESULTS: PET score was found to be the most significant predictor of survival in univariate and multivariate analysis (p 0.003). Patients having PET score 2 had poorer survival compared to both PET score 0 (p 0.001) and PET score 1 (p 0.004). Other covariates found to have significant correlation with survival were primary treatment modality and clinical symptoms at the time of recurrence.
CONCLUSION: FDG uptake on PET-CT is a strong predictor of survival in patients with suspected recurrent glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739222     DOI: 10.1007/s00234-011-0898-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  33 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms.

Authors:  D Kondziolka; J C Flickinger; D J Bissonette; M Bozik; L D Lunsford
Journal:  Neurosurgery       Date:  1997-10       Impact factor: 4.654

3.  Survival and functional status after resection of recurrent glioblastoma multiforme.

Authors:  F G Barker; S M Chang; P H Gutin; M K Malec; M W McDermott; M D Prados; C B Wilson
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

4.  Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.

Authors:  G Bauman; K Lote; D Larson; L Stalpers; C Leighton; B Fisher; W Wara; D MacDonald; L Stitt; J G Cairncross
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

5.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells.

Authors:  V Jung; B F Romeike; W Henn; W Feiden; J R Moringlane; K D Zang; S Urbschat
Journal:  J Neuropathol Exp Neurol       Date:  1999-09       Impact factor: 3.685

6.  Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.

Authors:  T J Janus; E E Kim; R Tilbury; J M Bruner; W K Yung
Journal:  Ann Neurol       Date:  1993-05       Impact factor: 10.422

7.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.

Authors:  D Kahn; K A Follett; D L Bushnell; M A Nathan; J G Piper; M Madsen; P T Kirchner
Journal:  AJR Am J Roentgenol       Date:  1994-12       Impact factor: 3.959

8.  Treatment and survival of low-grade astrocytoma in adults--1977-1988.

Authors:  B M McCormack; D C Miller; G N Budzilovich; G J Voorhees; J Ransohoff
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

9.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

10.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.

Authors:  C S Brock; H Young; S M O'Reilly; J Matthews; S Osman; H Evans; E S Newlands; P M Price
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  12 in total

1.  Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.

Authors:  Bangkim Chandra Khangembam; Sellam Karunanithi; Punit Sharma; Sudhir Suman Kc; Rajeev Kumar; Pramod Kumar Julka; Rakesh Kumar; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2014-07-03       Impact factor: 2.804

Review 2.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

3.  (11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas.

Authors:  Wanhu Li; Li Ma; Xiaoyue Wang; Jujie Sun; Suzhen Wang; Xudong Hu
Journal:  Tumour Biol       Date:  2014-09-03

4.  Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study.

Authors:  Jason R Buck; Eliot T McKinley; Allie Fu; Ty W Abel; Reid C Thompson; Lola Chambless; Jennifer M Watchmaker; James P Harty; Michael K Cooper; H Charles Manning
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

Review 5.  Accuracy of 11C-choline positron emission tomography in differentiating glioma recurrence from radiation necrosis: A systematic review and meta-analysis.

Authors:  Liansheng Gao; Weilin Xu; Tao Li; Jingwei Zheng; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.

Authors:  Ziren Kong; Yusong Lin; Chendan Jiang; Longfei Li; Zehua Liu; Yuekun Wang; Congxin Dai; Delin Liu; Xuying Qin; Yu Wang; Zhenyu Liu; Xin Cheng; Jie Tian; Wenbin Ma
Journal:  Cancer Imaging       Date:  2019-08-19       Impact factor: 3.909

7.  (68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study.

Authors:  Deling Li; Xiaobin Zhao; Liwei Zhang; Fang Li; Nan Ji; Zhixian Gao; Jisheng Wang; Peng Kang; Zhaofei Liu; Jiyun Shi; Xiaoyuan Chen; Zhaohui Zhu
Journal:  Mol Pharm       Date:  2014-08-11       Impact factor: 4.939

8.  Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma.

Authors:  Timothy P C Yeung; Slav Yartsev; Ting-Yim Lee; Eugene Wong; Wenqing He; Barbara Fisher; Lauren L VanderSpek; David Macdonald; Glenn Bauman
Journal:  J Med Radiat Sci       Date:  2014-01-16

Review 9.  Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma.

Authors:  Gloria C Chiang; Ilhami Kovanlikaya; Changho Choi; Rohan Ramakrishna; Rajiv Magge; Dikoma C Shungu
Journal:  Front Neurol       Date:  2018-02-05       Impact factor: 4.003

Review 10.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.